Evotec SE (EVO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Evotech SE half-year report 2025 conference call. I am Mathilde, the chorus call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Volker Braun, head of IR and ESG. Please go ahead. Thank you, Matilda, and good morning, good afternoon to everyone in the call. Thank you for joining us today. Today, we will cover our first half 2025 results, and we will discuss the progress we have made in the execution of our strategy as well as the key operational and external developments. We will, of course, also provide an update on the evolution of the Just Evotate Biologics business, of which the plant Sandoz deal is part of. However, because of the running process, we will not dwell in the details as such. We appreciate your understanding. Before we start, the usual 30 seconds on housekeeping items. On page two, we share the cautionary language with you. Some statements will be future-looking based on information available today, and they might be subject to change in future. But now let me hand over to the CEO of Evotech, Dr. Christian Wojcicki. Christian, please. Good afternoon and welcome to our H1 call. In April this year, we unveiled a new strategy, a strategy that sharpens our focus on pioneering drug discovery and development. With a plan to center our business around its core technology and scientific strengths, to cultivate operational excellence, and to place us o...